Kiora Pharmaceuticals vs PRF Technologies
KPRX and PRFX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KPRX | PRFX |
|---|---|---|
| Size and price | ||
| Market cap | $6.0M | – |
| Share price | $1.35 | $0.744 |
| Change, 1 year | −42.1% | −84.1% |
| Change, 5 years | −99.7% | −99.9% |
| Beta (5Y) | 0.82 | 1.61 |
| Employees | 3,500 | 6 |
| StockData Score | ||
| Total score | 6 | 6 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.4× | – |
| FCF yield | −132% | – |
| Profitability | ||
| Gross margin | – | −312% |
| Operating margin | – | −30129% |
| Net margin | – | −29541% |
| FCF margin | – | −23277% |
| Return on equity | −67.7% | −41.3% (better) |
| Return on invested capital | −1063% | −87.0% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 7.91 (better) | 5.07 |
| Altman Z-score | −10.63 | – |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 25.0% | 24.5% |
| Held by insiders | 3.0% | 24.1% |
| Short interest, % of float | – | 2.0% |
Go deeper
- KPRX stock overview
- KPRX income statement
- KPRX valuation and score
- PRFX stock overview
- PRFX income statement
- PRFX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.